ABT : Summary for Abbott Laboratories Common Stoc - Yahoo Finance

U.S. Markets close in 25 mins.

Abbott Laboratories (ABT)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
40.69-0.22 (-0.53%)
As of 3:35PM EST. Market open.
People also watch
ABBVBMYLLYJNJMRK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close40.90
Open41.05
Bid0.00 x
Ask0.00 x
Day's Range40.51 - 41.10
52 Week Range36.00 - 45.79
Volume3,413,071
Avg. Volume9,166,311
Market Cap70.02B
Beta1.49
PE Ratio (TTM)26.85
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.06 (2.59%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCURATE Study Confirms Superiority Of Abbott Laboratories (ABT) Dorsal Root Ganglion (DRG) Stimulation
    Insider Monkey5 hours ago

    ACCURATE Study Confirms Superiority Of Abbott Laboratories (ABT) Dorsal Root Ganglion (DRG) Stimulation

    Abbott Laboratories (NYSE:ABT)‘s dorsal root ganglion (DRG) stimulation therapy has advantages over traditional spinal cord stimulation (SCS) in the treatment of patients suffering from complex regional pain syndrome (CRPS). This is according to the latest data that was published in the January edition of Pain. The publication highlighted the real-world insight both in a short-term […]

  • PR Newswire8 hours ago

    Abbott Announces European Launch of the Proclaim™ DRG Neurostimulation System for the Management of Chronic Neuropathic Pain

    ABBOTT PARK, Ill., Jan. 18, 2017 /PRNewswire/ -- Abbott (ABT) today announced the European launch of the new Proclaim™ DRG Neurostimulation System, designed to deliver dorsal root ganglion (DRG) stimulation to patients suffering from chronic neuropathic pain. Through the Proclaim platform's Bluetooth® wireless technology and iOS™ software, the Proclaim DRG Neurostimulation System offers patients a more intuitive therapy experience, compared to current systems with traditional controllers that can be difficult to operate. This new system will improve the experience of how patients interact with their device, which may lead more patients to consider DRG stimulation for the treatment of chronic neuropathic pain.

  • PR Newswireyesterday

    New Data Confirms Abbott's Dorsal Root Ganglion Stimulation Offers Greater Treatment Success over Traditional Spinal Cord Stimulation

    ABBOTT PARK, Ill., Jan. 17, 2017 /PRNewswire/ -- New data published in the January edition of Pain has confirmed the superiority of Abbott's dorsal root ganglion (DRG) stimulation therapy over traditional spinal cord stimulation (SCS) for patients suffering from complex regional pain syndrome (CRPS). The data, which include both short-term and long-term data from the ACCURATE study, also suggested that DRG stimulation benefits patients' total mood and activity levels. Abbott is the only company in the world approved to offer DRG stimulation.